66F
N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide
Created: | 2016-02-03 |
Last modified: | 2016-11-09 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 45 |
Chiral Atom Count | 1 |
Bond Count | 47 |
Aromatic Bond Count | 12 |
Chemical Component Summary | |
---|---|
Name | N-{3-[(5R)-3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl]-4-fluorophenyl}-5-fluoropyridine-2-carboxamide |
Systematic Name (OpenEye OEToolkits) | ~{N}-[3-[(5~{R})-3-azanyl-2,5-dimethyl-1,1-bis(oxidanylidene)-6~{H}-1,2,4-thiadiazin-5-yl]-4-fluoranyl-phenyl]-5-fluoranyl-pyridine-2-carboxamide |
Formula | C17 H17 F2 N5 O3 S |
Molecular Weight | 409.41 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | c2(cc(NC(c1ncc(cc1)F)=O)ccc2F)C3(CS(=O)(N(C)C(N)=N3)=O)C |
SMILES | CACTVS | 3.385 | CN1C(=N[C](C)(C[S]1(=O)=O)c2cc(NC(=O)c3ccc(F)cn3)ccc2F)N |
SMILES | OpenEye OEToolkits | 2.0.4 | CC1(CS(=O)(=O)N(C(=N1)N)C)c2cc(ccc2F)NC(=O)c3ccc(cn3)F |
Canonical SMILES | CACTVS | 3.385 | CN1C(=N[C@@](C)(C[S]1(=O)=O)c2cc(NC(=O)c3ccc(F)cn3)ccc2F)N |
Canonical SMILES | OpenEye OEToolkits | 2.0.4 | C[C@]1(CS(=O)(=O)N(C(=N1)N)C)c2cc(ccc2F)NC(=O)c3ccc(cn3)F |
InChI | InChI | 1.03 | InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1 |
InChIKey | InChI | 1.03 | YHYKUSGACIYRML-KRWDZBQOSA-N |
Drug Info: DrugBank
DrugBank ID | DB12285 |
---|---|
Name | Verubecestat |
Groups | investigational |
Description | Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of 57, 79 and 84 percent, respectively. |
Synonyms | Verubecestat |
Categories |
|
CAS number | 1286770-55-5 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Beta-secretase 1 | MAQALPWLLLWMGAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEE... | unknown | inhibitor |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL3301601 |
PubChem | 51352361 |
ChEMBL | CHEMBL3301601 |
CCDC/CSD | EZIXUI |